Align Technologyreason 01 of 4it can hold its price and keep the customerderived 2026-09-08accession 0001097149-26-000060
Align possesses pricing power in its core Clear Aligner business, able to raise ASPs while simultaneously growing volume and doctor submitters even as management acknowledges orthodontic starts have declined for four consecutive years. This combination suggests the Invisalign brand commands enough clinical differentiation and patient demand that doctors continue prescribing it at higher prices despite a softening orthodontic market.
the thesis · admitted · the reason above is the thesis, not printed twice
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedthree sentences · whole, uncut
the claims it rests on
“For Q2 2026, Clear Aligner net revenues increased by $66 million compared to the same period in 2025, primarily due to an increase in volume, which increased net revenues by $53 million and an increase of $13 million from favorable foreign exchange rates and price increases.”
“For Q2 2026, the total number of Invisalign-trained doctors that submitted cases and received shipments (doctor submitters) was 89.2 thousand compared to 86.3 thousand in Q2 2025, a 3.4% increase.”
“For the three and six months ended June 30, 2026, our gross margin percentage increased as compared to the same periods in 2025 primarily due to tariff refunds, roll-off of accelerated depreciation and higher clear aligner ASPs.”